Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C

作者: Kazuaki Chayama , C. Nelson Hayes , Kentaro Yoshioka , Hisataka Moriwaki , Takashi Okanoue

DOI: 10.1007/S00535-010-0358-6

关键词: Viral loadCartCombination therapyImmunologyLogistic regressionHepatitis CInterferonGastroenterologyRibavirinInternal medicineHepatologyMedicine

摘要: Treatment of genotype 1b chronic hepatitis C virus (HCV) infection has been improved by extending peg-interferon plus ribavirin combination therapy to 72 weeks, but predictive factors are needed identify those patients who likely respond long-term therapy. We analyzed amino acid (aa) substitutions in the core protein and interferon sensitivity determining region (ISDR) nonstructural (NS) 5A 840 with high viral load. used logistic regression classification tree (CART) analysis for sustained virological response (SVR) undergoing weeks treatment. When were separately treatment duration using multivariate regression, several factors, including sex, age, load, aa70 ISDR (P = 0.0003, P = 0.02, P = 0.01, P = 0.0001, P = 0.0004, respectively) significant SVR 48 treatment, whereas previous history, (P = 0.03, only Using CART analysis, a decision was generated that identified cholesterol, length, as most important factors. The model had 69.2% specificity 60%, positive value 68.4%. Complementary statistical data mining approaches subgroup benefit from

参考文章(41)
N. Kato, M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, K. Shimotohno, Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis Proceedings of the National Academy of Sciences of the United States of America. ,vol. 87, pp. 9524- 9528 ,(1990) , 10.1073/PNAS.87.24.9524
Peter Ferenci, Hermann Laferl, Thomas–Matthias Scherzer, Andreas Maieron, Harald Hofer, Rudolf Stauber, Michael Gschwantler, Harald Brunner, Christoph Wenisch, Martin Bischof, Michael Strasser, Christian Datz, Wolfgang Vogel, Karin Löschenberger, Petra Steindl–Munda, Austrian Hepatitis Study Group, None, Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. ,vol. 138, pp. 503- 512 ,(2010) , 10.1053/J.GASTRO.2009.10.058
Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Sachiyo Watahiki, Junko Sato, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load Journal of Medical Virology. ,vol. 78, pp. 83- 90 ,(2006) , 10.1002/JMV.20507
J H Hoofnagle, Hepatitis C: the clinical spectrum of disease. Hepatology. ,vol. 26, pp. 15- 20 ,(1997) , 10.1002/HEP.510260703
Christoph Sarrazin, Eva Herrmann, Katharina Bruch, Stefan Zeuzem, Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses Journal of Virology. ,vol. 76, pp. 11079- 11090 ,(2002) , 10.1128/JVI.76.21.11079-11090.2002
Ahmed El-Shamy, Mikiko Sasayama, Motoko Nagano-Fujii, Noriko Sasase, Susumu Imoto, Soo Ryang Kim, Hak Hotta, Prediction of Efficient Virological Response to Pegylated Interferon/Ribavirin Combination Therapy by NS5A Sequences of Hepatitis C Virus and Anti-NS5A Antibodies in Pre-Treatment Sera Microbiology and Immunology. ,vol. 51, pp. 471- 482 ,(2007) , 10.1111/J.1348-0421.2007.TB03922.X
Francesc Puig-Basagoiti, Xavier Forns, Ivana Furčić, Sergi Ampurdanés, Mireia Giménez-Barcons, Sandra Franco, José M. Sánchez-Tapias, Juan-Carlos Saiz, Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C Journal of General Virology. ,vol. 86, pp. 1067- 1075 ,(2005) , 10.1099/VIR.0.80526-0
Maria Buti, Yoav Lurie, Natalia G Zakharova, Natalia P Blokhina, Andrzej Horban, Gerlinde Teuber, Christoph Sarrazin, Ligita Balciuniene, Saya V Feinman, Rab Faruqi, Lisa D Pedicone, Rafael Esteban, SUCCESS Study Investigators, None, Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response Hepatology. ,vol. 52, pp. 1201- 1207 ,(2010) , 10.1002/HEP.23816
I. Vuillermoz, E. Khattab, E. Sablon, I. Ottevaere, D. Durantel, C. Vieux, C. Trepo, Fabien Zoulim, Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. Journal of Medical Virology. ,vol. 74, pp. 41- 53 ,(2004) , 10.1002/JMV.20144
Salvador Augustin, Laura Muntaner, José T. Altamirano, Antonio González, Esteban Saperas, Joan Dot, Monder Abu–Suboh, Josep R. Armengol, Joan R. Malagelada, Rafael Esteban, Jaime Guardia, Joan Genescà, Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clinical Gastroenterology and Hepatology. ,vol. 7, pp. 1347- 1354 ,(2009) , 10.1016/J.CGH.2009.08.011